New CAR-T therapy trial aims to control tough leukemia
NCT ID NCT06287229
Summary
This study is testing whether a personalized immune cell therapy (called brexucabtagene autoleucel or brexu-cel) can help control B-cell acute lymphocytic leukemia (ALL) in adults. It is for people whose cancer has come back or didn't respond to treatment, or for those newly diagnosed with high-risk disease. The goal is to see if this therapy is safe and effective when given after a specific combination of other cancer drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.